Raffa Wealth Management, LLC
- SEC CIK
- 0001631073
- Latest filing
- Jul 27, 2026
TMO holding history
Thermo Fisher Scientific Inc. in every 13F filed by Raffa Wealth Management, LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
TMO overviewAll 13F holders of TMOFull Q2 2026 holdings
- Shares (Q2 2026)
- 63
- Value
- $31.6K
- % of portfolio
- <0.1%
- Quarters held
- 44
- Since Q4 2013
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 63 | $31.6K | <0.1% | +7+12.5% | Added | Holders |
| Q1 2026 | 56 | $27.5K | <0.1% | +2+3.7% | Added | Holders |
| Q4 2025 | 54 | $31.3K | <0.1% | +2+3.8% | Added | Holders |
| Q3 2025 | 52 | $25.2K | <0.1% | −42−44.7% | Reduced | Holders |
| Q2 2025 | 94 | $38.1K | <0.1% | +51+118.6% | Added | Holders |
| Q1 2025 | 43 | $21.4K | <0.1% | −3−6.5% | Reduced | Holders |
| Q4 2024 | 46 | $23.9K | <0.1% | −7−13.2% | Reduced | Holders |
| Q3 2024 | 53 | $32.8K | <0.1% | 00.0% | Unchanged | Holders |
| Q2 2024 | 53 | $29.3K | <0.1% | 00.0% | Unchanged | Holders |
| Q1 2024 | 53 | $30.8K | <0.1% | +3+6.0% | Added | Holders |
| Q4 2023 | 50 | $26.5K | <0.1% | −100−66.7% | Reduced | Holders |
| Q3 2023 | 150 | $75.9K | <0.1% | +4+2.7% | Added | Holders |
| Q2 2023 | 146 | $76.2K | <0.1% | 00.0% | Unchanged | Holders |
| Q1 2023 | 146 | $84.2K | <0.1% | 00.0% | Unchanged | Holders |
| Q4 2022 | 146 | $80.4K | <0.1% | +3+2.1% | Added | Holders |
| Q3 2022 | 143 | $72.5K | <0.1% | +2+1.4% | Added | Holders |
| Q2 2022 | 141 | $76.6K | <0.1% | 00.0% | Unchanged | Holders |
| Q1 2022 | 141 | $83.3K | <0.1% | 00.0% | Unchanged | Holders |
| Q4 2021 | 141 | $94.1K | <0.1% | 00.0% | Unchanged | Holders |
| Q3 2021 | 141 | $80.6K | <0.1% | 00.0% | Unchanged | Holders |
| Q2 2021 | 141 | $71.1K | <0.1% | +102+261.5% | Added | Holders |
| Q1 2021 | 39 | $17.8K | <0.1% | +9+30.0% | Added | Holders |
| Q4 2020 | 30 | $14.0K | <0.1% | 00.0% | Unchanged | – |
| Q3 2020 | 30 | $13.2K | <0.1% | 00.0% | Unchanged | – |
| Q2 2020 | 30 | $10.9K | <0.1% | 00.0% | Unchanged | – |
| Q1 2020 | 30 | $8.51K | <0.1% | 00.0% | Unchanged | – |
| Q4 2019 | 30 | $9.75K | <0.1% | 00.0% | Unchanged | – |
| Q3 2019 | 30 | $8.74K | <0.1% | +30 | New | – |
| Q2 2019 | 0 | $0 | 0.0% | −30−100.0% | Sold out | – |
| Q1 2019 | 30 | $8.21K | <0.1% | 00.0% | Unchanged | – |
| Q4 2018 | 30 | $6.71K | <0.1% | 00.0% | Unchanged | – |
| Q3 2018 | 30 | $7.32K | <0.1% | 00.0% | Unchanged | – |
| Q2 2018 | 30 | $6.21K | <0.1% | 00.0% | Unchanged | – |
| Q1 2018 | 30 | $6.19K | <0.1% | +30 | New | – |
| Q1 2017 | 0 | $0 | 0.0% | −9−100.0% | Sold out | – |
| Q4 2016 | 9 | $1.27K | <0.1% | 00.0% | Unchanged | – |
| Q3 2016 | 9 | $1.43K | <0.1% | 00.0% | Unchanged | – |
| Q2 2016 | 9 | $1.33K | <0.1% | 00.0% | Unchanged | – |
| Q1 2016 | 9 | $1.27K | <0.1% | 00.0% | Unchanged | – |
| Q4 2015 | 9 | $1.28K | <0.1% | 00.0% | Unchanged | – |
| Q3 2015 | 9 | $1.10K | <0.1% | 00.0% | Unchanged | – |
| Q2 2015 | 9 | $1.17K | <0.1% | 00.0% | Unchanged | – |
| Q1 2015 | 9 | $1.21K | <0.1% | 00.0% | Unchanged | – |
| Q4 2014 | 9 | $1.13K | <0.1% | 00.0% | Unchanged | – |
| Q3 2014 | 9 | $1.09K | <0.1% | +9 | New | – |
| Q1 2014 | 0 | $0 | 0.0% | −9−100.0% | Sold out | – |
| Q4 2013 | 9 | $1.13K | <0.1% | – | – | – |
Livermore's 13F data starts with Q4 2013, so Q4 2013 has no change from the previous quarter.